Item 2.02 Results of Operations and Financial Condition Regulation FD Disclosure

On January 12, 2021, C4 Therapeutics, Inc. (the "Company") posted a presentation to its website at https://ir.c4therapeutics.com/events-presentations that it expects to share with investors on or before January 14, 2021 in connection with the 39th Annual J.P. Morgan Healthcare Conference. On January 6, 2021, the Company issued a press release announcing its key milestones for 2021. In both the presentation and the press release, the Company disclosed that its unaudited cash, cash equivalents and short-term investments as of December 31, 2020 were approximately $370 million. A copy of the presentation is furnished herewith as Exhibit 99.1 and a copy of the applicable disclosure from the press release is furnished herewith as Exhibit 99.2.

The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2020 and its results of operations for the three months and year ended December 31, 2020. The audit of the Company's consolidated financial statements for the year ended December 31, 2020 is ongoing and could result in changes to the information set forth above.

Item 7.01 Regulation FD Disclosure

The contents of Item 2.02 of this Current Report on Form 8-K are incorporated herein by reference.

The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form.



Exhibit
Number    Description
99.1        Presentation of the Company dated January 2021 (furnished herewith)
            Disclosure on Cash, Cash Equivalents and Short-Term Investments
99.2      (furnished herewith)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses